The PARCC (Paris Cardiovascular Research Center, Inserm U970) succeeded in bringing together an important critical mass of basic and clinician scientists, who share a vision and common objectives in the field of cardiovascular diseases. PARCC teams are conducting projects, spanning basic molecular and cellular biology to integrated physiology and pathophysiology, biomarkers, genetics and epidemiology, with the goal of understanding, at a more refined and mechanistic level, disease processes in atherosclerosis, angiogenesis, hypertension, heart failure and sudden cardiac death, and also at the interface between cardiology and oncology. They are developing novel diagnostic and therapeutic strategies. Translational research is an integral part of the mission of the PARCC, in close connection with clinical laboratories and departments of the HEGP hospital.
The PARCC is part of the Université de Paris Cité and of the Institut des sciences cardiovasculaires de l’université de Paris
Novel Cardiokine GDF3 Predicts Adverse Fibrotic Remodeling After Myocardial Infarction . Circulation. 2023
Machine learning for classification of hypertension subtypes using multi-omics: A multi-centre, retrospective, data-driven study. EBioMedicine. 2022
Conserved meningeal lymphatic drainage circuits in mice and humans. J Exp Med. 2022
Endothelial Unc5B controls blood-brain barrier integrity. Nat Commun. 2022
See the actions of PARCC’s reaesrchers against #COVID-19More
If you want to join us, do not hesitate to upload your CV !Upload your CV